Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of March 2025, specifically dated March 3, 2025. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
| Metric | Value |
|---|---|
| Issued Share Capital (as of Feb 28, 2025) | 4,315,177,430 Ordinary Shares (31.25 pence each) |
| Treasury Shares | 173,023,905 |
| Total Voting Rights | 4,142,153,525 |
Material Changes
The filing text does not provide a clear value for material changes versus a prior comparable period. It presents a static snapshot of share capital as of February 28, 2025.
Guidance, Outlook, and Risks
The filing text does not provide clear values for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification intended to assist shareholders in calculating disclosure thresholds under FCA rules.
Important Facts for Investors
- Voting Rights Denominator: Shareholders should use 4,142,153,525 as the denominator to determine if they must notify the Company of their interest or changes thereto.
- Treasury Holdings: Approximately 173 million shares are held in Treasury and do not carry voting rights.
- Reporting Date: The share capital figures are accurate as of February 28, 2025.
- Contact for Notifications: Notifications regarding share interests should be sent to company.secretary@gsk.com.